ArticleThe Prostate2026
Impact of Intraprostatic Simultaneous Integrated Boost on Long-Term Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated With Dose-Escalated Radiotherapy and Short-Term Androgen Deprivation Therapy.
Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnfavorable intermediate-risk prostate cancer (UIR-PCa) represents a biologically heterogeneous subgroup with a higher risk of recurrence compared with favorable intermediate-risk disease. Contemporary management frequently includes dose-escalated radiotherapy (RT) combined with short-term androgen deprivation therapy (ADT). Whether additional intraprostatic dose escalation using a simultaneous integrated boost (SIB) provides incremental oncologic benefit in this setting remains uncertain.
methodsWe retrospectively analyzed 194 patients with UIR-PCa treated at three institutions between 2010 and 2023. All patients received image-guided intensity-modulated or volumetric modulated arc RT to 78 Gy with short-term ADT. An MRI-guided intraprostatic SIB (up to 86 Gy) was delivered in 77 patients (39.7%) at clinician discretion. Primary endpoints were biochemical recurrence-free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific mortality (PCSM). Multivariable Cox and competing-risk regression models were used to assess predictors of outcome.
resultsAfter a median follow-up of 105 months, 8-year bRFS and DMFS rates for the entire cohort were 93.7% and 95.7%, respectively. Addition of SIB was not associated with improved bRFS (93.5% vs 93.6%, p = 0.36), DMFS (94.6% vs 96.7%, p = 0.15), or PCSM. Percent positive biopsy cores ≥ 50% was the only independent predictor of inferior bRFS on multivariable analysis. Treatment-related toxicity was low in both groups, with no significant differences in late grade ≥ 2 gastrointestinal or genitourinary toxicity.
conclusionsIn patients with UIR-PCa uniformly treated with dose-escalated, image-guided RT and short-term ADT, long-term oncologic outcomes were excellent. The addition of an intraprostatic SIB was safe but did not confer measurable improvement in biochemical or distant disease control. These findings support a selective rather than routine use of focal intraprostatic dose escalation in contemporary UIR-PCa management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.